MedTrace Logo

MultiCenter expeRience in AFib Patients Treated With OAC (CRAFT)

NCT02987062 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2017-06-08

No results posted yet for this study

Summary

According to current guidelines for non-valvular atrial fibrillation treatment, the first line drugs are non-vitamin K oral anticoagulants (NOACs), which are preferred over vitamin K antagonists (VKAs). However, it is not clearly confirmed, how the success of NOACs approval trials (ROCKET-AF (rivaroxaban), RE-LY (dabigatran) and ARISTOTLE (apixaban) reflects on real-life clinical practice.

The aim of this study is to assess treatment of AF patients with oral anticoagulants (OACs) in an academic and district hospital, with regard to inclusion/exclusion criteria used in the clinical trials.

Conditions

Sponsors & Collaborators

  • Medical University of Warsaw

    lead OTHER

Principal Investigators

  • Grzegorz Opolski, Professor · 1st Department of Cardiology Medical University of Warsaw

  • Marcin Grabowski, PhD · 1st Department of Cardiology Medical University of Warsaw

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2017-04-30
Completion
2017-09-30

Countries

  • Poland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02987062 on ClinicalTrials.gov